Skip to main content
. 2022 Feb 9;17(2):e0261980. doi: 10.1371/journal.pone.0261980

Table 2. Main outcomes.

Placebo
(65)
HCQ
(62)
Crude Hazard ratio
(HR)
Adjusted
HR
Symptomatic COVID-19 infection 6/65
(9.2%)
1/62
(1.6%)
0.18 (0.02–1.48) 0.18 (0.21–1.59)
Adverse events 38/65
(58.5%)
32/62
(51.6%)
0.98 (0.94–1.03) 0.78 (0.38–1.59)